Neutral Alkem; target of Rs 5160: Motilal Oswal
Motilal Oswal recommended Neutral rating on Alkem with a target price of Rs 5160 in its research report dated February 21, 2024.22-02-2024
22-02-2024
Alkem Laboratories Ltd - 539523 - Disclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011
`The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Madhurima Singh & Others16-02-2024
Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Please find enclosed herewith the transcript of the ''Q3 FY2024 Earnings Conference Call'' which was hosted by the Company on Friday 09th February, 2024. The said transcript shall also be made available on the website of the Company.14-02-2024
Alkem Labs Q3 Results Review - India, International (ex-U.S.) Businesses Outperforms: Motilal Oswal
Steps up investments in biosimilar segment.12-02-2024
Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the audio recording of the 'Q3FY24 Earnings Conference Call' is available on the website of the Company at https://www.alkemlabs.com/earnings-call.php. Kindly take the same on records.09-02-2024
Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the audio recording of the 'Q3FY24 Earnings Conference Call' is available on the website of the Company at https://www.alkemlabs.com/earnings-call.php. Kindly take the same on records.09-02-2024
Q3FY24 Quarterly & 9MFY24 Result Announced for Alkem Laboratories Ltd.
Pharmaceuticals company Alkem Laboratories announced Q3FY24 & 9MFY24 results: Q3FY24 Financial Performance: Total Revenue from Operations: Rs 33,239 million, a YoY growth of 9.3%. India sales: Rs 22,328 million, a YoY growth of 12.1%. International sales: Rs 10,240 million, a YoY growth of 3.1%. EBITDA: Rs 7,076 million, resulting in an EBITDA margin of 21.3% compared to 19.7% in Q3FY23, indicating an 18.1% YoY increase. R&D; expenses: Rs 1,111 million, representing 3.3% of total revenue from operations, compared to Rs 1,297 million in Q3FY23 at 4.3% of total revenue from operations. Profit before tax (PBT) before exceptional item: Rs 7,062 million, a growth of 31.0% compared to Q3FY23. Net Profit (after Minority Interest): Rs 5,950 million, a YoY growth of 30.8%. 9MFY24 Financial Performance: Total Revenue from Operations: Rs 97,318 million, a YoY growth of 11.9%. India sales: Rs 64,613 million, a YoY growth of 7.9%. International sales: Rs 30,928 million, a YoY growth of 19.8%. EBITDA: Rs 18,435 million, resulting in an EBITDA margin of 18.9% compared to 14.4% in 9MFY23, indicating a 46.8% YoY increase. R&D; expenses: Rs 3,472 million, representing 3.6% of total revenue from operations, compared to Rs 3,922 million in 9MFY23 at 4.5% of total revenue from operations. Profit before tax (PBT) before exceptional item: Rs 17,648 million, a growth of 61.4% compared to 9MFY23. Net Profit (after Minority Interest): Rs 15,022 million, a YoY growth of 64.5%. Commenting on the results, Dr Vikas Gupta, CEO, Alkem said, "Continuing our trend of improved performance, Q3 builds on the momentum gained in H1 with significant gross margin enhancements backed by lower raw material cost and lower intensity of price erosion in US market resulting in improved EBITDA margins. Our domestic business has outperformed IPM growth by 20bps. Our international business has delivered steady growth, although US business de-grew on the back of the high base of last year led by flu season. In non-US business across geographies, we achieved very healthy growth. Our biosimilars business is performing impressively and witnessing significant traction in the domestic biosimilars market with Enzene’s portfolio of 7 products. We are committed to carrying forward the momentum of better operational performance, building on our recent successes." Result PDF09-02-2024
Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 and 47 read alongwith Schedule III of SEBI Listing Regulations, please find enclosed herewith a copy of advertisement published in today''s Newspaper viz. Business Standard (English) and Mumbai Lakshadeep (Marathi) as notice to shareholders informing the record date fixed for the Interim Dividend for Financial Year 2023-24, approved by Board of Directors at its meeting held on Friday, 09th February, 2024. Kindly take note of the same.09-02-2024
Alkem Laboratories Ltd - 539523 - Request For Reclassification Received From Certain Members Of Promoter Group Under Regulation 31A Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements), Regulations, 2015, As Amended ('SEBI Listing Regulations').
The BOD considered the request received from certain members of the Promoter Group namely Mr. Shikhar Raj, Ms. Sakshi Sinha and Mr. Satyam Sinha for reclassification from Promoter Group to Public Category09-02-2024
Alkem Laboratories Ltd - 539523 - Announcement Under Regulation 30 (LODR)- Cut-Off Date For Postal Ballot
The Company has fixed 23rd Feb as cut off date.09-02-2024